A retrospective efficacy and safety study of pembrolizumab/cetuximab neoadjuvant therapy in locally advanced hypopharyngeal cancer
PurposeThe primary objective of this study was to retrospectively assess the efficacy and safety profiles of two neoadjuvant regimens combining either pembrolizumab or cetuximab with paclitaxel and cisplatin in patients with locally advanced hypopharyngeal cancer (LAHPC).MethodsLAHPC patients who re...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1574988/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850212160577208320 |
|---|---|
| author | Guangnan Yao Guangnan Yao Guangnan Yao Xiaobo Wu Xiaobo Wu Xiaobo Wu Hanqing Lin Hanqing Lin Hanqing Lin Zhihong Chen Zhihong Chen Zhihong Chen Chang Lin Chang Lin Chang Lin Gongbiao Lin Gongbiao Lin Gongbiao Lin |
| author_facet | Guangnan Yao Guangnan Yao Guangnan Yao Xiaobo Wu Xiaobo Wu Xiaobo Wu Hanqing Lin Hanqing Lin Hanqing Lin Zhihong Chen Zhihong Chen Zhihong Chen Chang Lin Chang Lin Chang Lin Gongbiao Lin Gongbiao Lin Gongbiao Lin |
| author_sort | Guangnan Yao |
| collection | DOAJ |
| description | PurposeThe primary objective of this study was to retrospectively assess the efficacy and safety profiles of two neoadjuvant regimens combining either pembrolizumab or cetuximab with paclitaxel and cisplatin in patients with locally advanced hypopharyngeal cancer (LAHPC).MethodsLAHPC patients who received surgical resection at our hospital between August 2022 and February 2024 were enrolled in the study. All patients received neoadjuvant treatment before surgery and postoperative adjuvant therapy. They were categorized into two groups based on the neoadjuvant regimen: the paclitaxel + cisplatin + pembrolizumab (TP + PEMBRO) group and the paclitaxel + cisplatin + cetuximab (TP + CETUX) group. We evaluated various parameters including treatment response rate, adverse effects, surgical modalities, and survival outcomes for both groups.ResultsA total of 32 LAHPC patients were enrolled into the study, with 16 patients in each group. The TP + PEMBRO group demonstrated a significantly superior objective response rate (ORR) of neoadjuvant treatment compared to the TP + CETUX group (87.5% vs 68.75%, P < 0.05). In terms of surgical procedures, the TP + PEMBRO group exhibited a higher proportion of minimally invasive surgeries (87.5% vs 56.25%, P < 0.05), and both the tracheotomy rate and indwelling gastric tube rate were relatively lower in this group. Regarding patient prognosis, the 1-year overall survival (OS) rate in the TP + PEMBRO group was 100%, and the 1-year relapse-free survival (RFS) rate was 92.31%. In contrast, the TP + CETUX group had a 1-year OS rate of 93.75% and a 1-year RFS rate of 81.25%. There was no significant disparity in adverse events between the two groups, and no grade 3–4 severe adverse events occurred.ConclusionThe neoadjuvant TP regimen integrating pembrolizumab or cetuximab was associated with higher transoral surgery (TOS) rates and laryngeal preservation rates. Notably, the TP + PEMBRO regimen outperformed the TP + CETUX regimen in terms of treatment response rate and the proportion of minimally invasive surgeries, suggesting a novel and efficacious neoadjuvant treatment for LAHPC. |
| format | Article |
| id | doaj-art-a08b9800625847a3b75fb45f1e586ae4 |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-a08b9800625847a3b75fb45f1e586ae42025-08-20T02:09:24ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-06-011610.3389/fimmu.2025.15749881574988A retrospective efficacy and safety study of pembrolizumab/cetuximab neoadjuvant therapy in locally advanced hypopharyngeal cancerGuangnan Yao0Guangnan Yao1Guangnan Yao2Xiaobo Wu3Xiaobo Wu4Xiaobo Wu5Hanqing Lin6Hanqing Lin7Hanqing Lin8Zhihong Chen9Zhihong Chen10Zhihong Chen11Chang Lin12Chang Lin13Chang Lin14Gongbiao Lin15Gongbiao Lin16Gongbiao Lin17Department of Otolaryngology, Fujian Institute of Otorhinolaryngology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaFujian Branch Center of National Clinical Research Center for Otorhinolaryngologic Diseases , Fujian Clinical Research Center for Difficult Diseases of Otorhinolaryngology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Otolaryngology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, ChinaDepartment of Otolaryngology, Fujian Institute of Otorhinolaryngology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaFujian Branch Center of National Clinical Research Center for Otorhinolaryngologic Diseases , Fujian Clinical Research Center for Difficult Diseases of Otorhinolaryngology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Otolaryngology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, ChinaDepartment of Otolaryngology, Fujian Institute of Otorhinolaryngology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaFujian Branch Center of National Clinical Research Center for Otorhinolaryngologic Diseases , Fujian Clinical Research Center for Difficult Diseases of Otorhinolaryngology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Otolaryngology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, ChinaDepartment of Otolaryngology, Fujian Institute of Otorhinolaryngology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaFujian Branch Center of National Clinical Research Center for Otorhinolaryngologic Diseases , Fujian Clinical Research Center for Difficult Diseases of Otorhinolaryngology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Otolaryngology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, ChinaDepartment of Otolaryngology, Fujian Institute of Otorhinolaryngology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaFujian Branch Center of National Clinical Research Center for Otorhinolaryngologic Diseases , Fujian Clinical Research Center for Difficult Diseases of Otorhinolaryngology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Otolaryngology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, ChinaDepartment of Otolaryngology, Fujian Institute of Otorhinolaryngology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaFujian Branch Center of National Clinical Research Center for Otorhinolaryngologic Diseases , Fujian Clinical Research Center for Difficult Diseases of Otorhinolaryngology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Otolaryngology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, ChinaPurposeThe primary objective of this study was to retrospectively assess the efficacy and safety profiles of two neoadjuvant regimens combining either pembrolizumab or cetuximab with paclitaxel and cisplatin in patients with locally advanced hypopharyngeal cancer (LAHPC).MethodsLAHPC patients who received surgical resection at our hospital between August 2022 and February 2024 were enrolled in the study. All patients received neoadjuvant treatment before surgery and postoperative adjuvant therapy. They were categorized into two groups based on the neoadjuvant regimen: the paclitaxel + cisplatin + pembrolizumab (TP + PEMBRO) group and the paclitaxel + cisplatin + cetuximab (TP + CETUX) group. We evaluated various parameters including treatment response rate, adverse effects, surgical modalities, and survival outcomes for both groups.ResultsA total of 32 LAHPC patients were enrolled into the study, with 16 patients in each group. The TP + PEMBRO group demonstrated a significantly superior objective response rate (ORR) of neoadjuvant treatment compared to the TP + CETUX group (87.5% vs 68.75%, P < 0.05). In terms of surgical procedures, the TP + PEMBRO group exhibited a higher proportion of minimally invasive surgeries (87.5% vs 56.25%, P < 0.05), and both the tracheotomy rate and indwelling gastric tube rate were relatively lower in this group. Regarding patient prognosis, the 1-year overall survival (OS) rate in the TP + PEMBRO group was 100%, and the 1-year relapse-free survival (RFS) rate was 92.31%. In contrast, the TP + CETUX group had a 1-year OS rate of 93.75% and a 1-year RFS rate of 81.25%. There was no significant disparity in adverse events between the two groups, and no grade 3–4 severe adverse events occurred.ConclusionThe neoadjuvant TP regimen integrating pembrolizumab or cetuximab was associated with higher transoral surgery (TOS) rates and laryngeal preservation rates. Notably, the TP + PEMBRO regimen outperformed the TP + CETUX regimen in terms of treatment response rate and the proportion of minimally invasive surgeries, suggesting a novel and efficacious neoadjuvant treatment for LAHPC.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1574988/fullhypopharyngeal cancerneoadjuvant therapypembrolizumabcetuximabminimally invasive surgeryorgan preservation |
| spellingShingle | Guangnan Yao Guangnan Yao Guangnan Yao Xiaobo Wu Xiaobo Wu Xiaobo Wu Hanqing Lin Hanqing Lin Hanqing Lin Zhihong Chen Zhihong Chen Zhihong Chen Chang Lin Chang Lin Chang Lin Gongbiao Lin Gongbiao Lin Gongbiao Lin A retrospective efficacy and safety study of pembrolizumab/cetuximab neoadjuvant therapy in locally advanced hypopharyngeal cancer Frontiers in Immunology hypopharyngeal cancer neoadjuvant therapy pembrolizumab cetuximab minimally invasive surgery organ preservation |
| title | A retrospective efficacy and safety study of pembrolizumab/cetuximab neoadjuvant therapy in locally advanced hypopharyngeal cancer |
| title_full | A retrospective efficacy and safety study of pembrolizumab/cetuximab neoadjuvant therapy in locally advanced hypopharyngeal cancer |
| title_fullStr | A retrospective efficacy and safety study of pembrolizumab/cetuximab neoadjuvant therapy in locally advanced hypopharyngeal cancer |
| title_full_unstemmed | A retrospective efficacy and safety study of pembrolizumab/cetuximab neoadjuvant therapy in locally advanced hypopharyngeal cancer |
| title_short | A retrospective efficacy and safety study of pembrolizumab/cetuximab neoadjuvant therapy in locally advanced hypopharyngeal cancer |
| title_sort | retrospective efficacy and safety study of pembrolizumab cetuximab neoadjuvant therapy in locally advanced hypopharyngeal cancer |
| topic | hypopharyngeal cancer neoadjuvant therapy pembrolizumab cetuximab minimally invasive surgery organ preservation |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1574988/full |
| work_keys_str_mv | AT guangnanyao aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT guangnanyao aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT guangnanyao aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT xiaobowu aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT xiaobowu aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT xiaobowu aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT hanqinglin aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT hanqinglin aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT hanqinglin aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT zhihongchen aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT zhihongchen aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT zhihongchen aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT changlin aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT changlin aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT changlin aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT gongbiaolin aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT gongbiaolin aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT gongbiaolin aretrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT guangnanyao retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT guangnanyao retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT guangnanyao retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT xiaobowu retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT xiaobowu retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT xiaobowu retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT hanqinglin retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT hanqinglin retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT hanqinglin retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT zhihongchen retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT zhihongchen retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT zhihongchen retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT changlin retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT changlin retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT changlin retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT gongbiaolin retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT gongbiaolin retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer AT gongbiaolin retrospectiveefficacyandsafetystudyofpembrolizumabcetuximabneoadjuvanttherapyinlocallyadvancedhypopharyngealcancer |